This study is in progress, not accepting new patients
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Melvin Heyman
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Melvin Heyman
Professor, Pediatrics, School of Medicine. Authored (or co-authored) 321 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Hoffmann-La Roche
- ID
- NCT02118584
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- About 1822 people participating
- Last Updated